Latigo Biotherapeutics, Inc. Market Research Report

Background

Company Overview

Latigo Biotherapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered in Thousand Oaks, California. Established in 2018, the company is dedicated to developing innovative non-opioid pain medicines aimed at effectively and rapidly alleviating pain without the risk of addiction. Latigo's mission is to disrupt traditional pain therapy by providing safer alternatives to opioid-based treatments. The company is supported by leading investors, including Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital.

Mission and Vision

Latigo's mission is to develop best-in-class non-opioid pain medicines that target the fundamental mechanisms of pain transduction. The company's vision is to provide effective, rapid-acting pain relief without the risk of addiction, thereby improving patient outcomes and quality of life.

Industry Significance

The biotechnology industry, particularly in the realm of pain management, is experiencing significant growth due to the increasing demand for non-addictive pain therapies. Latigo's focus on non-opioid pain medicines positions it at the forefront of this critical sector, addressing a substantial unmet need in the market.

Key Strategic Focus

Core Objectives

• Development of Non-Opioid Pain Therapies: Latigo is committed to creating innovative pain treatments that provide effective relief without the risks associated with opioid use.

• Advancement of Clinical Programs: The company aims to progress its pipeline of non-opioid pain medicines through various stages of clinical development.

Areas of Specialization

• Nav1.8 Inhibitors: Latigo specializes in developing selective Nav1.8 inhibitors, targeting a validated human pain pathway to address both acute and chronic pain.

Key Technologies Utilized

• Advanced Drug Discovery Techniques: The company employs cutting-edge artificial intelligence, machine learning, structure-based, and knowledge-based design methods to optimize drug potency and selectivity.

Primary Markets Targeted

• Acute and Chronic Pain Management: Latigo focuses on providing non-opioid solutions for the treatment of acute and chronic pain conditions, aiming to reduce reliance on traditional opioid therapies.

Financials and Funding

Total Funds Raised

Latigo has secured a total of $285 million in funding across multiple rounds.

Recent Funding Rounds

• Series B Financing (April 17, 2025): The company raised $150 million in a Series B round led by funds managed by Blue Owl Capital, with participation from Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital. Existing investors Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments also participated.

Notable Investors

• Blue Owl Capital

• Deep Track Capital

• Access Biotechnology

• Qatar Investment Authority

• Cormorant Asset Management

• Sanofi Ventures

• Rock Springs Capital

• UPMC Enterprises

• Kern Capital

• Westlake Village BioPartners

• Foresite Capital

• 5AM Ventures

• Alexandria Venture Investments

Utilization of Capital

The funds from the Series B financing are intended to support the advancement of Latigo's Nav1.8 inhibitor clinical programs and the development of its broader pipeline of non-opioid pain therapeutics.

Pipeline Development

Key Pipeline Candidates

• LTG-001: An oral, selective Nav1.8 inhibitor in development for the treatment of acute pain. The Phase 1 clinical trial demonstrated favorable safety and tolerability profiles, with predictable pharmacokinetics. In March 2025, the FDA granted Fast Track designation to LTG-001, facilitating its development and expedited regulatory review.

• LTG-305: Another oral, selective Nav1.8 inhibitor currently in Phase 1 clinical trials, targeting chronic pain. The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of LTG-305 in healthy volunteers.

Anticipated Milestones

• LTG-001: Advancement through subsequent clinical trial phases, with the aim of obtaining regulatory approvals for acute pain indications.

• LTG-305: Completion of Phase 1 trials and progression to later-stage clinical trials for chronic pain indications.

Technological Platform and Innovation

Proprietary Technologies

• Nav1.8 Inhibitor Development: Latigo's proprietary technology focuses on developing selective Nav1.8 inhibitors, a validated target for pain management.

Significant Scientific Methods

• Advanced Drug Discovery Techniques: The company utilizes artificial intelligence, machine learning, structure-based, and knowledge-based design methods to optimize drug candidates.

Leadership Team

Executive Profiles

• Nima Farzan – Chief Executive Officer: With over two decades of experience in the biopharmaceutical industry, Nima has a strong track record in fundraising and leading companies through successful IPOs. Prior to joining Latigo, he served as CEO of Kinnate Biopharma, leading the company through a $270 million IPO and its eventual sale to Xoma Corporation.

• Neha Krishnamohan – Chief Financial Officer and Chief Business Officer: Neha brings more than 15 years of experience in healthcare investment banking and biotech financial leadership. She previously served as CFO and EVP of Corporate Development at Artiva Biotherapeutics and Kinnate Biopharma.

• Neil Singla – Chief Medical Officer: An expert in analgesic protocol design, Neil has been instrumental in pioneering methodologies that enhance the rigor and outcomes of pain management studies. He chairs the Clinical Trials Special Interest Group for the International Association for the Study of Pain (IASP).

• Sabrina Nieder – Vice President, Corporate Controller: Sabrina has over 15 years of experience in corporate accounting and operations, including IPO readiness and establishing internal controls. She has served as Corporate Controller at both private and publicly traded companies in the life science industry.

• Julia Chapman – Senior Vice President, Program & Portfolio Management: Julia leads the strategic planning and operational execution of Latigo's portfolio of non-opioid medicines for acute and chronic pain. She has over 15 years of experience in advancing complex therapeutic programs from discovery to commercialization.

• Bryan Moyer, PhD – Senior Vice President, Discovery: Bryan has more than 20 years of experience in research and development, leading drug discovery teams for target identification and clinical candidate delivery. He co-founded Latigo Biotherapeutics and previously led discovery programs at Amgen.

Leadership Changes

• April 8, 2026: Sara M. Bonstein was appointed to Latigo's Board of Directors and as Chair of the Audit Committee. Sara brings over two decades of financial and operational leadership in biotech, including her current role as CFO of Insmed.

Competitor Profile

Market Insights and Dynamics

The global pain management market is experiencing significant growth, driven by the increasing prevalence of chronic pain conditions and the need for non-addictive pain therapies. The shift towards non-opioid treatments is a key trend, with companies like Latigo Biotherapeutics leading the charge in developing innovative solutions.

Competitor Analysis

• LTS Lohmann Therapie-Systeme: Develops and manufactures transdermal drug delivery systems for pharmaceutical active substances.

• Andromaco: A pharmaceutical company.

• Esteve: A company that manufactures and supplies pharmaceuticals.

• KSQ Therapeutics: Develops and deploys precision functional genomics to discover drug therapies.

Strategic Collaborations and Partnerships

Latigo has established strategic collaborations with leading investors and partners to advance its mission of developing non-opioid pain medicines. These partnerships provide financial support, strategic guidance, and resources essential for the company's growth and success.

Operational Insights

Latigo's focus on non-opioid pain therapies, its strong pipeline centered around Nav1.8 inhibitors, and robust investor backing position it for advancement in the pain management market niche.